Gendicine is a gene therapy medication used to treat patients with head and neck squamous cell carcinoma linked to mutations in the TP53 gene. It consists...

trials were conducted, with more than half of them in phase I. In 2003, Gendicine became the first gene therapy to receive regulatory approval. Since that...

a viable cancer treatment option. The first commercial gene therapy, Gendicine, was approved in China in 2003 for the treatment of head and neck squamous...

imatinib 2002  – The State Food and Drug Administration of China approves Gendicine, gene therapy for cancer 2002  – Corporate takeover of Dupont by BMS resulted...

settings. In 2003, China approved the first gene therapy for clinical use: Gendicine, an adenoviral vector encoding p53. In 2012, the European Union issued...

first gene therapy product to be licensed to treat cancer, Gendicine, is an adenovirus. Gendicine, an adenoviral p53-based gene therapy was approved by the...

However, cetuximab's efficacy is still under investigation by researchers. Gendicine is a gene therapy that employs an adenovirus to deliver the tumor suppressor...

a step forward and a step back; first gene therapy drug was approved, Gendicine, which was approved in China for the treatment of certain cancers, but...

Exagamglogene autotemcel (Casgevy): treatment for sickle cell disease. Gendicine: treatment for head and neck squamous cell carcinoma Idecabtagene vicleucel...